Combination therapy for advanced endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs, anlotinib and TQB2450, for people with advanced endometrial cancer that has not responded to previous chemotherapy. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or recurrent endometrial cancer that has spread or come back.
- You have already tried 1 or 2 lines of platinum-based chemotherapy, and it didn't work.
- You are not a candidate for surgery or radiation to cure the cancer.
- You are 18 or older and in reasonably good health (able to care for yourself).
- You have not been treated with certain other targeted or immunotherapy drugs before.
- You are willing to use effective birth control during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (camrelizumab and anlotinib) for patients with a specific type of endometrial cancer that has returned or spread. The drug combo aims to boost your immune system to fight the cancer while also cutting off its blood supply. It is for patients whose tumor has a certain genetic feature and who have already tried chemotherapy.
This trial tests a new immunotherapy drug (QL1706) for people with advanced endometrial cancer whose previous immunotherapy stopped working. It aims to see if this different approach can help when standard treatments have failed.
This trial tests a new combination of drugs for advanced solid tumors. It may help if your cancer has not responded to other treatments, and the goal is to see how safe and effective this new approach is.
This trial tests a combination of three drugs (pembrolizumab, lenvatinib, and an immune booster called N-803) plus a personalized vaccine made from your own cells, all aimed at helping your immune system fight advanced or metastatic endometrial cancer that has HER2 protein on its surface.
This trial tests whether adding a targeted drug (fruquintinib) to standard chemotherapy works better than chemotherapy alone as the first treatment for advanced or recurrent endometrial cancer that is pMMR. It may help control the cancer for a longer time.
This trial tests a new combination of drugs (TQB2868 injection plus anlotinib capsules) compared to standard chemotherapy for people with pancreatic cancer that has spread to other parts of the body and has not been treated before.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.